137.07 USD
-0.5 (-0.36%)
138.25 USD
+1.18 (+0.86%)
Taking everything into account, TMDX scores 6 out of 10 in our fundamental rating. TMDX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. TMDX has only an average score on both its financial health and profitability. TMDX is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
TMDX had a positive operating cash flow in the past year.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX's Return On Assets of 9.70% is amongst the best of the industry. TMDX outperforms 93.51% of its industry peers.
The Return On Equity of TMDX (25.84%) is better than 96.76% of its industry peers.
The Return On Invested Capital of TMDX (8.75%) is better than 88.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of TMDX (16.20%) is better than 92.97% of its industry peers.
TMDX's Operating Margin of 16.94% is amongst the best of the industry. TMDX outperforms 87.57% of its industry peers.
With a decent Gross Margin value of 60.28%, TMDX is doing good in the industry, outperforming 61.62% of the companies in the same industry.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
TMDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TMDX has more shares outstanding
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
TMDX has an Altman-Z score of 5.82. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 5.82, TMDX is doing good in the industry, outperforming 79.46% of the companies in the same industry.
TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
TMDX's Debt to FCF ratio of 4.24 is fine compared to the rest of the industry. TMDX outperforms 80.00% of its industry peers.
A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.43, TMDX is not doing good in the industry: 78.38% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.82 |
ROIC/WACC0.93
WACC9.45%
2.3 Liquidity
TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
TMDX's Current ratio of 7.69 is amongst the best of the industry. TMDX outperforms 88.11% of its industry peers.
A Quick Ratio of 7.13 indicates that TMDX has no problem at all paying its short term obligations.
The Quick ratio of TMDX (7.13) is better than 88.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.23% on average per year.
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TMDX is valuated quite expensively with a Price/Earnings ratio of 55.49.
TMDX's Price/Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 68.65% of the companies in the same industry.
TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.19.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 46.39.
TMDX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 69.73% of the companies in the same industry.
TMDX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.49 | ||
| Fwd PE | 46.39 |
4.2 Price Multiples
69.19% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
76.22% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.84 | ||
| EV/EBITDA | 39.01 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 53.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
137.07
-0.5 (-0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.19%
Inst Owner Change0%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.68B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (8.59%)
Short Float %21.09%
Short Ratio7.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.74%
PT rev (3m)-0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.49 | ||
| Fwd PE | 46.39 | ||
| P/S | 8.27 | ||
| P/FCF | 38.84 | ||
| P/OCF | 26.26 | ||
| P/B | 13.19 | ||
| P/tB | 13.71 | ||
| EV/EBITDA | 39.01 |
EPS(TTM)2.47
EY1.8%
EPS(NY)2.95
Fwd EY2.16%
FCF(TTM)3.53
FCFY2.57%
OCF(TTM)5.22
OCFY3.81%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.34
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.82 |
F-Score7
WACC9.45%
ROIC/WACC0.93
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.